For participants who have been found to have gone through seroconversion to HIV-1 at the first quarterly check out, plasma samples that had been obtained during enrollment were examined for HIV-1 RNA; if the samples were positive, the few was excluded from the analyses because HIV-1 infection occurred before randomization. Associates of an adjudication committee who were professionals in HIV-1 sequencing and had been unaware of the procedure assignments reviewed the sequencing data and offered a consensus classification of linkage . Statistical Analysis We estimated that with an example of 3646 couples who were discordant for HIV-1 serologic status and a follow-up period of 12 a few months, and with the assumption that 85 percent of the transmissions of HIV-1 would be linked, 88 linked transmissions of HIV-1 would occur and the study would have 90 percent capacity to detect a 50 percent reduction in the incidence of HIV-1 an infection in the acyclovir group in comparison with the placebo group , at a two-sided type I error rate of 5 percent.Related StoriesInnovation in anaesthesia: an interview with Matti Lehtonen, GE HealthcareLiposomal sizing and the Coulter theory: an interview with Professor Melvin E. KlegermanExpanded use for IntelliCap with further CE Mark for aspiration of fluidsThe NDA seeks acceptance to market ILUVIEN , an investigational, sustained drug delivery program that releases sub-microgram degrees of fluocinolone acetonide for the treatment of DME. The ILUVIEN NDA was submitted to the FDA on June 29, 2010 with security and efficacy data through month 24 of the FAME Study. On August 30 The FDA granted the NDA Concern Review position, 2010. In the CRL, the FDA asked for analyses of efficacy and security data through month 36 of the FAME Research, including exploratory analyses in addition to those submitted in the NDA previously, to assess the relative benefits and risks of ILUVIEN further.